pembrolizumab
merck
['pembro', 'sclc', 'lung', 'lcsm,(-blcsm)', 'nsclc']
#asco23 lung orals kn798 chemo-pembro v chemo alone in egfrmt nsclc post tki: - pfs hr 0.8 p=0.01 (mpfs 5.6 v 5.5m)
- os hr 0.84 p=0.03 (mos 15.9 v 14.7m)
- did not meet reqmts or pre-specified stats plan, &amp; not a clinically meaningful difference #lcsm 
Professor of Medical Oncology @CancerCentreIre | Thoracic Oncologist | Immunotherapy & Immune toxicity | Adjunct faculty Johns Hopkins University